FerriScan Case Study Challenge
- 21 December 2015
FerriScan R2-MRI is now the recognised global gold standard in measurement of liver iron concentration. It has largely replaced liver biopsy in many countries, saving patients the discomfort and risks associated with invasive procedures. The scientific rigor underpinning FerriScan’s calibration and validation, together with the quality-assured service delivery, means that clinicians now confidently use the reported results to monitor their patients’ liver iron concentration (LIC) and to optimise their treatment.
30,000 FerriScans and ASH
- 04 December 2015
Resonance Health is exhibiting at the American Society of Hematology (ASH) Conference in Orlando Florida from 5 – 8 December.
Resonance Health News September 2015
- 02 October 2015
Resonance Health is happy to provide you with an update on our recent activity via our latest quarterly newsletter.
To read the newsletter please click here
Resonance Health Appoints New Distributor, KNS in Canada
- 24 September 2015
Resonance Health is pleased to announce the appointment of KNS in Canada who will launch a local presence for FerriScan at the forthcoming 2015 Pan-Canadian Thalassemia Conference taking place in Toronto on September 25-26th.
St Mary’s Hospital Celebrates 1000 FerriScans From Perth to Paddington!
- 23 September 2015
St Mary’s Hospital has become one of the first hospitals in Europe to reach a milestone of providing 1000 FerriScans (the Gold Standard for measuring Liver Iron Concentration) for children and adult patients.
HEPAFAT-SCAN® FATTY LIVER STUDY COMMENCES IN THE USA
- 21 August 2015
We are excited to announce that the paediatric fatty liver disease study using HepaFat-Scan has now commenced in the USA. It is being run in collaboration with the prestigious children’s hospital, Children’s Healthcare of Atlanta. At the date of this release, approximately ten patients have already been recruited and had HepaFat-Scans completed for the study, which commenced last month.